BSE: 524348
To view real time prices Login to your account
Already an existing customer? - Login Now!
BSE Click here to view BSE data
Live Chart
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
Div yield:

Fundamental analysis


0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Underperformed both Sector by -3.6% and Sensex by -16.81%
MARKET CAP (Small Cap Stock)Rs 3,488 Cr
PE (TTM) 21.53
PE Ratio21.53
Price to Book Value3.21
EV to EBIT16.70
EV to EBITDA13.87
EV to Capital Employed2.46
EV to Sales1.55
PEG Ratio0.00
Dividend Yield0.26%
ROCE (Latest)15.89%
ROE (Latest)16.86%
NameDec 22Sep 22
Promoters (Change:-0.11) 59.66%59.77%
FIIs (Change:-0.04) 1.9%1.94%
Mutual Funds (Change:0.74) 3.82%3.08%
Insurance Companies (Change:0.00) 0.08%0.08%
Other DIIs (Change:0.01) 0.01%0%
Non Institution (Change:-0.60) 34.53%35.13%

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000


Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %


Frequently Asked Questions

What is the Share price of AARTI DRUGS LTD. (AARTIDRUGS)?

AARTI DRUGS LTD. (AARTIDRUGS) share price as of March 22, 2023, on NSE is Rs 375.80 (NSE) and Rs 375.65 (BSE) on BSE.


Yes, You can buy AARTI DRUGS LTD. (AARTIDRUGS) shares by opening a Demat account with Angel One.

How do I buy AARTI DRUGS LTD. (AARTIDRUGS) from Angel One?

AARTI DRUGS LTD. (AARTIDRUGS) share can be brought through the following modes:
  1. Direct investment: You can buy AARTI DRUGS LTD. (AARTIDRUGS) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to AARTI DRUGS LTD. (AARTIDRUGS) shares.

In which sector do AARTI DRUGS LTD. (AARTIDRUGS) belong?

AARTI DRUGS LTD. (AARTIDRUGS) belongs to Pharma.

Is Aarti Drugs a Debt free Company?

No, Aarti Drugs is not a debt free company.

What is the main business of Aarti Drugs?

The main business of Aarti Drugs is to manufacture and sell Active Pharmaceutical Ingredients (APIs), formulations, speciality chemicals, and pharma intermediates through its 12 GMP certified manufacturing plants.

Who are the promoters of Aarti Drugs?

Some of the main promoters of Aarti Drugs are Prakash Moreshwar Patil, Seema Harshit Savla, Harshit Manilal Savla, Rashesh Chandrakant Gogri, Priti Prakash Patil, Gogri Finserv Pvt. Ltd., Hetal Gogri Gala, Anushakti Enterprise Private Limited, Mirik Rajendra Gogri, and Renil Rajendra Gogri.

What are the Subsidiaries that comes under Aarti Drugs?

The main subsidiaries that come under Aarti Drugs are Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, and Pinnacle Chile SpA.


Today's live share price for AARTI DRUGS LTD is NSE: ₹ 375.80, BSE: ₹ 375.65 with a current market capitalization of .

Aarti Drugs Ltd is one of the leading pharmaceutical manufacturers in India. The company is engaged manufacturing of pharmaceuticals. ADL operates in the anti-diarrhea, anti-inflammatory and anti-biotic therapeutic segments. They manufacture vitamins, anti-arthritis, anti-fungal, antibiotics, antibiotics and angiotensin converting enzyme (ACE) inhibitors in their manufacturing units located at Tarapur and Sarigam. They are having their R&D center at Tubhe, Navi Mumbai The manufacturing units of the company are GMP certified. Their products include active pharmaceutical ingredients, steroids, pharmaceutical intermediates, and specialty chemicals, such as benzene sulphonyl chloride, benzene sulphonic acid/ ammonium/ sodium salt and benzene sulphonamide. They are having one subsidiary company, namely Suyash Laboratories Ltd. Aarti Drugs Ltd, a part of Aarti Group of Industries, was incorporated in the year 1984. In the year 1993, the company implemented the second phase of their backward integration project and set up facilities for glyoxal (the main raw material for imidazoles). During the year 1994-95, the company commissioned a plant to recover and market ammonium sulphate derived from plant effluents. Also, Rupal Chemical Industries, a group company, was amalgamated with the company. During the year 1996-97, the company started their production of secnidazole and dichlofenac sodium. During the year 2000-01, they started the commercial production of Pharmaceutical Ingredients. During the year 2002-03, the company expanded the production capacity of bulk drugs by 598,000 kg to 17,430,000 kg. During the year 2003-04, the company further expanded the production capacity of bulk drugs by 588,000 kg to 18,018,000 kg. During the year 2004-05, the company started commercial production at their newly setup intermediate plant at Tarapur. During the year 2005-06, the company increased the production capacity of Pharmaceutical by 2,325,000 kg to 24,020,000 kg. They entered into joint venture with Chinese company engaged in Active Pharmaceutical Ingredients (APIs) manufacturing and formed Huanggang Yinhe Aarti Pharmaceutical Company Ltd for manufacturing and selling of APIs in China. Also, they acquired controlling stake in Suyash Laboratories Ltd so as to make the said company a subsidiary of the company. During the year 2006-07, the company increased the production capacity by 570,000 kg to 24,590,000 kg. During the next year, they increased the production capacity by 399,000 kg to 24,989,000 kg. During the year 2008-09, they further increased the production capacity of Pharmaceutical by 50,000 kg to 25,000,000 kg. During the year 2009-10, the company carried out research and development work/ process improvement work in bulk drugs, such as antihistaminic/anti-allergic, anti-inflammatory and anti-diabetic. ADL has sold/exported intermediates, such as Stage-I of pioglitazone and AU-% for tamsulosin. They expanded the production capacity from 25,000,000 kg to 25,716,000 kg. The company is expanding their production capacity in various products-lines to cope up the demand. They are also in the process of acquiring ISO 9002 compliance for all their units.

Read more

Enjoy Zero Brokerage on Equity Delivery

Join our 1 Cr+ happy customers